Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
复制标题
DOI：
10.1148/rg.352140164
复制
发表时间：
2015-03-01
期刊：
影响因子：
5.5
通讯作者：
Hicks, Rodney J.
中科院分区：
文献类型：
--
作者：
Hofman, Michael S.;Lau, W. F. Eddie;Hicks, Rodney J.
镓68（Ga-68）1，4，7，10-四氮杂环十二烷-1，4，7，10-四乙酸（DOTA）-奥曲酸盐（DOTATATE，GaTate）正电子发射断层扫描（PET）/计算机断层扫描（CT）是一种用于检测和表征神经内分泌肿瘤（NET）的成像技术。GaTate是一种生长抑素类似物，最近被美国食品和药物管理局授予孤儿药地位，从而增加了对这种放射性示踪剂的兴趣和可用性。GaTate PET/CT允许对生长抑素受体（SSTR）的细胞表面表达进行全身成像，并迅速发展成为NET检测和表征的新成像参考标准。作者讨论了GaTate PET/CT的正常表现以及该模式在各种肿瘤中的实用性，包括胃肠道、胰腺和支气管NET以及嗜铬细胞瘤、副神经节瘤、脑膜瘤和致癌性骨软化症。此外，他们还讨论了假阳性结果的潜在原因，包括胰腺钩突活动、炎症、成骨细胞活动和脾组织增生。他们还强调了2-[氟-18]氟-2-脱氧-d-葡萄糖（FDG）PET/CT的补充作用，包括使用GaTate PET/CT和FDG PET/CT评估分化良好和分化不良疾病部位的优势。与FDG PET/CT一起使用GaTate PET/CT可以识别肿瘤异质性，这提供了预后信息，并可以在指导活检中发挥关键作用。它还允许优化患者管理，包括肽受体放射性核素治疗的治疗诊断应用，以及治疗后患者的再分期。(C)RSNA，2015年。
Gallium 68 (Ga-68) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography (CT) is an imaging technique for detecting and characterizing neuroendocrine tumors (NETs). GaTate, a somatostatin analog, has recently been accorded orphan drug status by the U.S. Food and Drug Administration, thereby increasing interest in and availability of this radiotracer. GaTate PET/CT allows whole-body imaging of cell surface expression of somatostatin receptors (SSTRs) and is rapidly evolving as the new imaging standard of reference for the detection and characterization of NETs. The authors discuss the normal appearance at GaTate PET/CT and the utility of this modality in a variety of these tumors, including gastrointestinal, pancreatic, and bronchial NETs as well as pheochromocytoma, paraganglioma, meningioma, and oncogenic osteomalacia. In addition, they discuss potential causes of false-positive findings, including pancreatic uncinate process activity, inflammation, osteoblastic activity, and splenosis. They also highlight the complementary role of 2-[fluorine-18] fluoro-2-deoxy-d-glucose (FDG) PET/CT, including the advantages of using both GaTate PET/CT and FDG PET/CT to evaluate sites of well-and poorly differentiated disease. The use of GaTate PET/CT together with FDG PET/CT allows identification of tumor heterogeneity, which provides prognostic information and can be pivotal in guiding biopsy. It also allows optimal patient management, including theranostic application of peptide receptor radionuclide therapy, and the restaging of patients following therapy. (C) RSNA, 2015.